Abstract
Over the past two decades, the oncogenic protein kinase pp60src (Src) has been the focus of tremendous biological investigations that have identified it to be a promising therapeutic target for both cancer and bone disease drug discovery. The molecular, cellular and in vivo functional properties of Src provide a detailed framework for strategies to advance small molecule inhibitors relative to both its noncatalytic (e.g., SH2) and catalytic (i.e., kinase) domains. This chapter illustrates phoshopeptide mimetic-based small molecule Src SH2 inhibitors and ATP mimetic-based, small molecule Src kinase inhibitors. Key lead compounds exemplifying Src SH2 and Src kinase inhibitors are described with respect to structural biology, drug design and biological activity (in vitro and in vivo). The term SMART refers to small molecule ARIAD therapeutics that has been particularly focused on generating and optimizing novel lead compounds such as AP22408 and AP23464. AP22408 is a prototype bone-targeted Src SH2 inhibitor that blocks binding to phosphorylated ligands and was first to achieve in vivo proof-of-concept in a bone disease model. AP23451 is a second-generation, bone-targeted Src inhibitor and determined to be effective in both osteolytic bone metastasis and osteoporosis in vivo models. AP23464 is a prototype Src kinase inhibitor that is competitive to ATP and is extraordinarily potent in vitro and provides proof-of-concept in Src-dependent, cell assays representing both bone degrading osteoclasts and cancer cells. X-ray crystallographic structures of the aforementioned Src SH2 and Src kinase inhibitors provide insight to SMART drug design strategies. Second-generation Src kinase inhibitors are amidst preclinical and clinical drug development, and such small molecules illustrate varying template classes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abu-Amer, Y., Ross, F.P., Schlesinger, P., Tondravi, M.M., and Teitelbaum, S.L. (1997). Substrate recognition by osteoclast precursors induces c-Src/microtubule association. J. Cell Biol. 137:247–258.
Alexandropoulos, K., and Baltimore, D. (1996). Coordinate activation of c-Src by SH3-and SH2-binding sites on a novel p130Cas-related protein, Sin. Genes Dev. 10:1341–1355.
Alfaro-Lopez, J., Yuan, W., Phan, B.C., Kamath, J., Lou, Q., Lam, K.S., and Hruby, V.J. (1998). Discovery of a novel series of potent and selective substrate-based inhibitors of pp60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J. Med. Chem. 41:2252–2260.
Alligood, K.J., Charifson, P.S., Crosby, R., Consler, T.G., Feldman, P.L., Gampe, R.T. Jr., Gilmer, T.M., Jordan, S.R., Milstead, M.W., Mohr, C., Peel, M.R., Rocque, W., Rodriguez, M., Rusnak, D.W., Shewchuk, L.M., and Sternbach, D.D. (1998). The formation of a covalent complex between a dipeptide ligand and the SRC SH2 domain. Bioorg. Med. Chem. Lett. 8:1189–1194.
Avizienyte, E., Wyke, A.W., Jones, R.J., McLean, G.W., Westhoff, M.A., Brunton, V.G., and Frame, M.C. (2002). Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat. Cell Biol. 4:632–638.
Belsches-Jablonski, A.P., Biscardi, J.S., Peavy, D.R., Tice, D.A., Romney, D.A., and Parsons, S.J. (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20:1464–1475.
Biscardi, J.S., Tice, D.A., and Parson, S.J. (1999). c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. 76:61–119.
Bishop, A.C., and Shokat, K.M. (1999). Acquisition of inhibitor-senstive protein kinases through protein design. Pharmacol. Ther. 82:337–346.
Bishop, A.C., Shah, K., Liu, Y., Witucki, L, Kung, C., and Shokat, K.M. (1998). Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol. 8:257–266.
Blake, R.A., Broome, M.A., Liu, X., Wu, J., Gishizky, M., Sun, L., and Courtneidge, S.A. (2000). SU6656, a selective Src family kinase inhibitor used to probe growth factor signaling. Mol. Cell. Biol. 20:9018–9027.
Bohacek, R.S., Dalgarno, D.C., Hatada, M., Jacobsen, V.A., Lynch, B.A., Macek, K.J., Merry, T., Metcalf, C.A. III, Narula, S.S., Sawyer, T.K., Shakespeare, W.C., Violette, S.M., and Weigele, M. (2001). X-ray structure of citrate bound to Src SH2 leads to high-affinity, bone-targeted Src SH2 inhibitor. J. Med. Chem. 44:660–663.
Boschelli, D.H. (2002). 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. 2:1051–1063.
Boschelli, D.H., Wang, Y.D., Ye, F., Wu, B., Zhang, N., Dutia, M., Powell, D.W., Wissner, A., Arndt, K., Weber, J.M., Boschelli, F. (2001). Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 44:822–833.
Boschelli, D.H., Wang, Y.D., Johnson, S., Wu, B., Ye, F., Barrios Sosa, A.C., Golas, J.M., and Boschelli, F. (2004). 7-Alkoxy-4-phenylamino-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 47:599–601.
Boyce, B.F., Yoneda, T., Lowe, C., Soriano, P., and Mundy, G.R. (1992). Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90:1622–1627.
Boyce, B.F., Xing, L., Shakespeare, W., Wang, Y., Dalgarno, D., Iuliucci, J., and Sawyer, T. (2003). Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int. 85:52–55.
Bradshaw, J.M., and Waksman, G. (2002). Molecular recognition by SH2 domains. Adv. Protein Chem. 61:161–210.
Bridges, A.J. (1995). The emerging role of protein phosphoryation and cell cycle control in tumor progression. ChemTracts Org. Chem. 8:73–107.
Bridges, A.J. (2001a). Chemical inhibitors of protein kinases. Chem. Rev. 101:2541–2572.
Bridges, A.J. (2001b). Current progress towards the development of tyrosine kinase inhibitors as anticancer agents. In: Bowman, W.C., Fitzgerald, J.D., Taylor, J.B. (eds.), Emerging Drugs: The Prospect for Improved Medicines. Ashley Publications, London, pp.:279–292.
Brugge, J.S., and Erikson, R.L. (1977). Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 269:346–348.
Buchanan, J.L., Bohacek, R.S., Luke, G.P., Hatada, M., Lu, X., Dalgarno, D.C., Narula, S.S., Yuan, R., and Holt, D.A. (1999). Structure-based design and synthesis of a novel class of Src SH2 inhibitors. Bioorg. Med. Chem. Lett. 9:2353–2358.
Burke, T.R., Jr., and Lee, K. (2003). Phosphotyrosyl mimetics in the development of signal transduction inhibitors. Acc. Chem. Res. 36:426–400.
Burke, T.R., Jr., Yao, Z.-J., Liu, D.-G., Voigt, J., and Gao, Y. (2001). Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers (Peptide Sci.) 60:32–44.
Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Veccio, G., Fusco, A., Gazit, A., Levitzki, A., and Santoro, M. (2002). The kinase inhibitor PP1 blocks tumorogenesis induced by RET oncogenes. Cancer Res. 62:1077–1082.
Catlett-Falcone, R., Dalton, W.S., and Jove, R. (1999). STAT proteins as novel targets for cancer therapy. Signal transducer and activatior of transcription. Curr. Opin. Oncol. 11:490–496.
Clackson, T., Metcalf C.A., III, Rozamus, L.W., Rivera, V.M., Knowles, H.L., Wardwell, S.D., Wang, X., Burns, K.D., Roses, J.B., Graytock, C., Pradeepan, S., Notari, S.D., Bohacek, R.S., Berstein, D.L., Weigele, M., Dalgarno, D.C., and Iuliucci, J.D. (2002). Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc. AACR 43:ALB-95.
Cody, W.L., Lin, Z., Panek, R.L., Rose, D.W., and Rubin, J.R. (2000). Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des. 6:59–98.
Collet, M.S., and Erikson, R.L. (1978). Protein kinase activity associated with avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA 75:2021–2024.
Dalgarno, D.C., Botfield, M.C., and Rickles, R.J. (1997). SH3 domains and drug design: ligands, structure, and biological function. Biopolymers (Peptide Sci.) 43:383–400.
Dalgarno, D.C., Metcalf, C.A., Shakespeare, W.C., and Sawyer, T.K. (2000). Signal transduction drug discovery: targets, mechanisms, and structure-based design. Curr. Opin. Drug Dis. Dev. 3:549–564.
Dalgarno, D., Bohacek, R., Stehle, T., Narula, S., Metcalf III, C., Shakespeare, W., Sundaramoorthi, R., Keenan, T., Wang, Y., Keats, J. Ram, M., Adams, S., van Schravendijk, M.R., Weigele, M. and Sawyer, T.K. (2003). Structure-based design and X-ray crystallographic analysis of a potent and selective Src tyrosine kinase inhibitor for the treatment of cancer. In: AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, November 17–23, Boston, MA, Abstract A5.
Deprez, P., Baholet, I., Burlet, S., Lange, G., Amengual, R., Schoot, B., Vermond, A., Mandine, E., Lesuisse, D. (2002a). Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures. Bioorg. Med. Chem. Lett. 12:1291–1294
Deprez, P., Mandine, E., Gofflo, D., Meunier, S., and Lesuisse, D. (2002b). Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein. Bioorg. Med. Chem. Lett. 12:1295–1298.
Dreyer, M.K., Borcherding, D.R., Dumont, J.A., Peet, N.P., Tsay, J.T., Wright, P.S., Bitonti, A.J., Shen, J., and Kim, S.H. (2001). Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44:524–530.
Dumas, J. (2001). Protein kinase inhibitors: emerging pharmacophores 1997-2000. Expert Opin. Ther. Patents 11:405–429.
Duong, L.T., Lakkakorpi, P.T., Nakamura, I., Machwate, M., Nagy, R.M., and Rodan, G.A. (1998). Pyk2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activation by ligation of alpha(v)beta3 integrin and phosphorylated by Src kinase. J. Clin. Invest. 102:881–892.
Egan, C., Pang, A., Durda, D., Cheng, H.C., Wang, J.H., and Fujita, D.J. (1999). Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 18:1227–1237.
Eliceiri, B.P., Paul, R., Schwartzbert, P.I., Hood, J.D., Leng, J., and Cheresch, D.A. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4:915–924.
Ellis, L.M., Staley, C.A., Liu, W., Fleming, R.Y., Parikh, N.U., Bucana, C.D., and Gallick, G.E. (1998). Downregulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src. J. Biol. Chem. 273:1052–1057.
Erpel, T., and Courtneidge, S.A. (1995). Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7:176–182.
Fleisch, H. (2001), Bisphosphonates: mechanisms of action. Expert Opini. Ther. Patents 11:1371–1381.
Frame, M.C. (2002). Src in cancer: deregulation and consequences for cell behavior. Biochim. Biophys. Acta 1602:114–130.
Gane, P.J., and Dean, P.M. (2000). Recent advances in structure-based rational drug design. Curr. Opin. Struct. Biol. 10:401–404.
Garcia-Echevarria, C. (2001). Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. Curr. Med. Chem. 8:589–604.
Geddes, A.D., D’Souaza, S.M., Ebetino, F.H., and Ibbotson, K.J. (1994). Bisphosphonates: structure activity relationships and therapeutic implications. Bone Miner. Res. 8:265–306.
Gilmer, T., Rodriguez, M., Jordan, S., Crosby, R., Alligood, K., Green, M., Kimery, M., Wagner, C., Kinder, D., Charifson, P., Hassell, A.M., Willard, D., Luther, M., Rusnak, D., Sternbach, D.D., Mehrotra, M., Peel, M., Shampine, L., Davis, R., Robbins, J., Patel, I.R., Kassel, D., Burkhart, W., Moyer, M., Bradshaw, T., and Berman, J. (1994). Peptide inhibitors of Src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 269:31711–31719.
Gmeiner, W.H., and Horita, D.A. (2001). Implications of SH3 domain structure and dynamics for protein regulation and drug design. Cell Biochem. Biophys. 35:127–140.
Gould, C. and Wong, C.F. (2002). Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis. Pharmacol. Ther. 93:169–178.
Gray, N.S., Wodicka, L., Thunnissen, A.M., Norman, T.C., Kwon, S., Espinoza, F.H., Morgan, D.O., Barnes, G., LeClerc, S., Meijer, L., Kim, S.H., Lockhart, D.J., and Schultz, P.G. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533–538.
Hall, T.J., Schaeriblin, M., and Missbach, M. (1994). Evidence that c-Src is involved in the process of osteoclastic bone resorption. Biochem. Biophys. Res. Commun. 199:1237–1244.
Hamby, J.M., Connolly, C.J., Schroeder, M.C., Winters, R.T., Showalter, H.D., Panek, R.L., Major, T.C., Olsewski, B., Ryan, M.J., Dahring, T., Lu, G.H., Keiser, J., Amar, A., Shen, C., Kraker, A.J., Slintak, V., Nelson, J.M., Fry, D.W., Bradford, L., Hallak, H., and Doherty, A.M. (1997). Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 40:2296–2303.
Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Brissette, W.H., Weringer, E.J., Pollok, B.A., and Connelly, P.A. (1996). Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:695–701.
Hatada, M.H., Lu, X., Laird, E.R., Green, J., Morgenstern, J.P., Lou, M., Marr, C.S., Phillips, T.B., Ram, M.K., Theriault, K., Zoller, M.J., and Karas, J.L. (1995). Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 377:32–38.
Hubbard, S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:5572–5581.
Hunter, T., and Sefton, B.M. (1980). Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA 77:1311–1315.
Huron, D.R., Corre, M.E., Kraker, A.J., Sawyers, C.L., Rosen, N., and Moasser, M.M. (2003). A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-Abl-driven K562 cells and is effective against STI571-resistant Bcr-Abl mutants. Clin. Cancer Res. 9:1267–1273.
Irby, R.B., Mao, W., Coppola, D., Kang, J., Loubeau, J.M., Trudeau, W., Karl, R., Fujita, D.J., Jove, R., and Yeatman, T.J. (1999). Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21:187–190.
Jeschke, M., Brandi, M.-L., and Susa, M. (1998). Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1. J. Bone Miner. Res. 13:1880–1889.
Joseph-McCarthy, D. (1999). Computational approaches to structure-based ligand design. Pharmacol. Ther. 84:179–191.
Karni, R., Jove, R., and Levitzki, A. (1999). Inhibition of pp60c-Src reduces Bcl-Xl expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18:4654–462.
Kawahata, N., Yang, M.G., Luke, G.P., Shakespeare, W.C., Sundaramoorthi, R., Wang, Y., Johnson, D., Merry, T., Violette, S., Guan, W., Bartlett, C., Smith, J., Hatada, M., Lu, X., Dalgarno, D.C., Eyermann, C.J., Bohacek, R.S., and Sawyer, T.K. (2001). A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60src SH2 domain. Bioorg. Med. Chem. Lett. 11:2319–2323.
Kauffman, E.C., Robinson, V.L., Stadler, W.M., Sokoloff, M.H., and Rinker-Schaeffer, C.W. (2003). Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169:1122–1133.
Klebe, G. (2000). Recent developments in structure-based drug design. J. Mol. Med. 78:269–281.
Klohs, W.D., Fry, D.W., and Kraker, A.J. (1997). Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 9:562–268.
Klutchko, S.R., Hamby, J.M., Boschelli, D.H., Wu, Z., Kraker, A.J., Amar, A.M., Hartl, B.G., Shen, C., Klohs, W.D., Steinkampf, R.W., Driscoll, D.L., Nelson, J.M., Elliott, W.L., Roberts, B.J., Stoner, C.L., Vincent, P.W., Dykes, D.J., Panek, R.L., Lu, G.H., Major, T.C., Dahring, T.K., Hallak, H., Bradford, L.A., Showalter, H.D., and Doherty, A.M. (1998). 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 41:3276–3292.
Kraker, A.J., Hartl, B.G., Amar, A.M., Barvian, M.R., Showalter, H.D., and Moore, C.W. (2000). Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60:885–898.
Kraybill, B.C., Elkin, L.L. Blethrow, J.D., Morgan, D.O., and Shokat, K.M. (2002). Inhibitor scaffolds as new allele specific kinase substrates. J. Am. Chem. Soc. 124:12118–121128.
Lamers, M.B., Antson, A.A., Hukbbard, R.E., Scott, R.K., and Williams, D.H. (1999). Structure of Cterminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 28:713–725.
Lange, G., Lesuisse, D., Deprez, P., Schoot, B., Loenz, P., Marquette, J.-P., Broto, P., Sarubbi, E., and Mandine, E. (2002). Principles governing the binding of a class of non-peptidic inhibitors to the SH2 domain of Src studied by X-ray analysis. J. Med. Chem. 45:2915–2922.
Lawrence, D.S., and Niu, J. (1998). Protein kinase inhibitors: the tyrosine-specific kinases. Pharmacol. Ther. 77:81–114.
Legraverend, M., Tunnah, P., Noble, M., Ducrot, P., Ludwig, O., Grierson, D.S., Leost, M., Meijer, L., and Endicott, J. (2000). Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43:1282–1292.
Lesuisse, D., Deprez, P., Albert, E., Duc, T.T., Sortais, B., Goffe, D., Jean-Baptiste, V., Marquette, J.-P., Schoot, B., Sarubbi, E., Lange, G., Broto, P., and Mandine, E. (2001a). Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding. Bioorg. Med. Chem. Lett. 11:2127–2131.
Lesuisse, D., Deprez, P., Bernard, D., Broto, P., Delettre, G., Jean-Baptiste, V., Marquette, J.P., Sarubti, E., Schoot, B., Mandine, E., and Lange, G. (2001b). SAR by crystallography: a new approach combining screening and rational drug design. Application to the discovery of nanomolar Src SH2 binders. Chim. Nouv. 19:3240–3241.
Lesuisse. D., Lange, G., Deprez, P., Benard, D., Schoot, B., Delettre, G., Marquette, J.P., Broto, P., Jean-Baptiste, V., Bichet, P., Sarubbi, E., and Mandine, E. (2002). SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 45:2379–2387.
Levinson, A.D., Oppermann, H., Levintow, L., Varmus, H.E., and Bishop, J.M. (1978). Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell 15:561–572.
Levitzki, A., and Gazit, A. (1995). Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788.
Lowell, C.A., and Soriano, P. (1996). Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev. 10:1845–1857.
Lunney, E.A., Para, K.S., Plummer, M.S., Shahripour, A., Holland, D., Rubin, J.R., Humblet, C., Fergus, J., Marks, J., Hubbell, S., Herrera, R., Saltiel, A.R., and Sawyer, T.K. (1997). Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain. J. Am. Chem. Soc. 119:12471–12476.
Lutz, M.P., Esser, I.B., Flossmann-Kast, B.B., Vogelmann, R., Luhrs, H., Friess, H., Buchler, M.W., and Adler, G. (1998). Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 243:503–508.
Maa, M.-C., Leu, T.H., McCarley, D.J., Schatzman, R.C., and Parsons, S.J. (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA 92:6981–6985.
Maly, D.J., Choong, I.C., and Ellman, J.A. (2000). Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. USA 97:2419–2424.
Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., and Yeatman, T.J. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15:3083–3090.
Martin, G.S. (2001). The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2:467–475.
Marzia, M., Sims, N.A., Voit, S., Migliaccio, S., Taranta, A., Bernardini, S., Faraggiana, T., Yoneda, T., Mundy, G.R., Boyce, B.F., Baron, R., and Teti, A. (2000). Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151:311–320.
McMahon, G., Sukn, L., Liang, C., and Tang, C. (1998). Protein kinase inhibitors: structural determinants for target specificity. Curr. Opin. Drug Disc. Dev. 1:131–146.
McMartin, C., and Bohacek, R.S. (1997). QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Design 11:333–344.
McTigue, M.A., Wickersham, J.A., Pinko, C., Showalter, R.E., Parast, C.V., Tempczyk-Russell, A., Gehring, M.R., Mroczkowski, B., Kan, C.C., Villafranca, J.E., and Appelt, K. (1999). Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Struct. Fold. Des. 7:319–330.
Menke, A., Philipp, C., Vogelmann, R., Seidel, B., Lutz, M.P., Adler, G., and Wedlich, D. (2001). Downregulation of E-cadherin gene expression by collagen type I and type II in pancreatic cell lines. Cancer Res. 61:3508–3517.
Metcalf, C.A., and Sawyer, T.K. (2004). Src homology-2 domains and structure-based, small molecule library approaches to drug discovery. In: (A. Makriyannis, A., and Biegel, D. (eds.), Drug Discovery Strategies and Methods. Marcel Dekker, New York, pp. 23–59.
Metcalf III., C.A., Vu, C.B., Sundaramoorthi, R., Jacobsen, V.A., Laborde, E.A., Green, J., Green, Y., Macek, K.J., Merry, T.J., Pradeepan, S.G., Uesugi, M., Varkhedkar, V.M., and Holt, D.A., (1998). Novel phosphate ester-linked resins: the solid-phase generation of phenyl phosphate-containing compounds for SH2 inhibition. Tetrahed. Lett. 39:3435–3438.
Metcalf III, C.A., Eyermann, C.J., Bohacek, R.S., Haraldson, C.A., Varkhedkar, V.M., Lynch, B.A., Barlett, C., Violette, S.M., and Sawyer, T.K. (2000). Structure-based design and parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain. J. Comb. Chem. 2:305–313.
Metcalf, C., van Schravendijk, M.R., Dalgarno, D., and Sawyer, T.K. (2002). Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Design 8:2049–2075.
Metcalf, C., III, Wang, Y., Shakespeare, W., Sundaramoorthi, R., Keenan, T., Dalgarno, D., Bohacek, R., Burns, K., Roses, J., van Schravendijk, M.R., Ram, M., Keats, J., Liou, S., Adams, S., Snodgrass, J., Rivera, V., Weigele, M., Iuliucci, J., Clackson, T., Frame, M., Brunton, V., and Sawyer, T. (2003a). Structure-based methods to design potent and selective Src/Abl dual inhibitors and their development as antileukemic and antimetastatic agents. In: ACS Abstracts (226th ACS National Meeting). New York Sept 7–11, 2003.
Metcalf, C., III, Wang, Y., Shakespeare, W., Sundaramoorthi, R., Keenan, T., Dalgarno, D., Bohacek, R., Burns, K., Roses, J., van Schravendijk, M.R., Ram, M., Keats, J., Liou, S., Rivera, V., Weigele, M., Iuliucci, J., Clackson, T., Brunton, V., and Sawyer, T. (2003b). Discovery of potent and selective Src inhibitors and their development as antitumor and antimetastatic agents. Proc. AACR 44:A1716.
Metcalf III, C.A., Bohacek, R., Rozamus, L.W., Burns, K.D., Roses, J.B., Rivera, V.M., Tang, H., Keats, J.A., Dalgarno, D.C., Snodgrass, J., Berstein, D.L., Weigele, M., and Clackson, T. (2004). Structurebased design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc. AACR 45:A2476.
Missbach, M., Jeschke, M., Feyen, J., Muller, K., Glatt, M., Green, J., Susa, M. (1999). A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437–449.
Missbach, M., Attmann, E., and Susa, M. (2000). Tyrosine kinase inhibition in bone metabolism. Curr. Opin. Drug Disc. 3:541–548.
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B.K., Hubbard, S.R., and Schlessinger, J. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955–960.
Mohammadi, M., Froum, S., Hamby, J.M., Schroeder, M.C., Panek, R.L., Lu, G.H., Eliseenkova, A.V., Green, D., Schlessinger, J., and Hubbard, S.R. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase. EMBO J. 17:5896–5904.
Muller, G. (2000). Peptidomimetic SH2 domain antagonists for targeting signal transduction. Top. Curr. Chem. 211:17–59.
Musacchio, A. (2002). How SH3 domains recognize proline. Adv. Protein Chem. 61:211–268.
O’Hare, T., Pollock, R., Stoffreger, E.P., Keats, J.A., Abdullah, O.M., Moseson, E.M., Rivera, V.M., Tang, H., Metcalf III, C.A., Bohacek, R.S., Wang, Y., Sundaramoorthi, R., Shakespeare, W.C., Dalgarno, D.C., Clackson, T., Sawyer, T.K., Deininger, M.W., Drucker, B.J. (2004). Inhibition of wild-type and mutant Bcr-Abl by Ap23464, a potent ATP-bised oncogenic protein kinas: inhibitor: Implications for CML. Blood 104:2532–2539.
Para, K., Lunney, E.A., Plummer, M., Stankovic, C.J., Shahripour, A., Holland, D., Rubin, J.R., Humblet, C., Fergus, J., Marks, J., Hubbell, S., Herrera, R., Saltiel, A.R., and Sawyer, T.K. (1999). Structure-based de novo design and discovery of nonpeptide antagonists of the pp60src SH2 domain. In: Tam, J., and Kaumaya, P. (eds.), Proceedings of the Fifteenth American Peptide Symposium. Kluwer, Dordrecht, The Netherlands, pp. 173–175.
Paul, R., Zhang, Z.G., Eliceiri, B.P., Jiang, Q., Boccia, A.D., Zhang, R.L., Chopp, M., and Cheresh, D.A. (2001). Src deficiency or blockade of Src activity in mice provides cerebral protection during stroke. Nat. Med. 7:222–227.
Pawson, T. (2004). Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116:191–203.
Ple, P.A., Green, T.P., Hennequin, L.F., Curwen, J., Fennell, M., Allen, J., Lambert-van der Brempt, C., and Costello, G. (2004). Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J. Med. Chem. 47:871–887.
Plummer, M.S., Lunney, E.A., Para, K.S., Prasad, J.V., Shahripour, A., Singh, J., Stankovic, C.J., Humblet, C., Fergus, J.H., Marks, J.S., and Sawyer, T.K. (1996). Hydrophobic D-amino acids in the design of peptide ligands for the pp60src SH2 domain. Drug Des. Discov. 13:75–81.
Plummer, M.S., Holland, D.R., Shahripour, A., Lunney, E.A., Fergus, J.H., Marks, J.S., McConnell, P., Mueller, W.T., and Sawyer, T.K. (1997a). Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand J. Med. Chem. 40:3710–3725.
Plummer, M.S., Lunney, E.A., Para, K.S., Shahripour, A., Stankovic, C.J., Humblet, C., Fergus, J.H., Marks, J.S., Herrera, R., Hubbell, S., Saltiel, A., and Sawyer, T.K. (1997b). Design of peptidomimetic ligands for the pp60src SH2 domain. Bioorg. Med. Chem. 5:41–47.
Rahuel, J., Gay, B., Erdmann, D., Strauss, A., Garcia-Echeverria, C., Furet, P., Caravatti, G., Fretz, H., Schoepfer, J., and Grutter, M.G. (1996). Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat. Struct. Biol. 3:586–589.
Ramdas, L., Bunnin, B.A., Plunkett, M.J., Sun, G., Ellman, J., Gallick, G., and Budde, R.J.A. (1999). Benzodiazepine compounds as inhibitors of the Src protein tyrosine kinase: screening of a combinatorial library of 1,4-benzodiazepines. Arch. Biochem. Biophys. 368:394–300.
Recchia, I., Rucci, N., Festuccia, C., Bologna, M., MacKay, A.R., Migliaccio, S., Longo, M., Susa, M., Fabbro, D., and Teti, A. (2003). Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur. J. Cancer 39:1927–1935.
Recchia, I., Rucci, N., Funari, A., Migliaccio, S., Taranta, A., Longo, M., Kneissel, M., Susa, M., Fabbro, D., Teti, A. (2004). Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 34: 65–79.
Rickles, R.J., Henry, P.A., Guan, W., Azimioara, M., Shakespeare, W.C., Violette, S., Zoller, M.J. (1998). A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific proteinprotein inhibitors. Chem. Biol. 5:529–538.
Rogers, M.J. (2003). New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9:2643–2658.
Rogers, M.J., Gordon, S., Benford, H.L., Coxon, FP., Luckman, SP., Monkkonen, J, and Frith JC: (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12, Suppl.): 2961–2978.
Russello, S.V., and Shore, S.K. (2003). Src in human carcinogenesis. Front. Biosci. 8:1068–1073.
Sawyer, T.K. (2004). Novel dual Src/Abl kinase inhibitors for cancer therapy. Keystone Symposium on Protein Kinases and Cancer: The Promise of Molecular-Based Therapies, February 24–29 2004, Tahoe City. CA.
Sawyer, T.K., Boyce, B., Dalgarno, D., and Iuliucci, J. (2001). Src inhibitors: genomics to therapeutics. Expert Opin. Invest. Drugs 10:1327–1344.
Sawyer, T.K., Bohacek, R.S., Dalgarno, D.C., Eyermann, C. J., Kawahata, N., Metcalf, C., Shakespeare, W.C., Sundaramoorthi, R., Wang, Y., and Yang, M. (2002). Mini Rev. Med. Chem. 2:475–489.
Sawyer, T.K., Bohacek, R.S., Metcalf, C.A., III, Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Keenan, T., Narula, S., Weigele, M., Dalgarno, D.C. (2003). Novel protein kinase inhibitors: SMART drug design technology. BioTechniques (Suppl) June:2–15.
Scapin, G. (2000). Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 7:601–611.
Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., and Kuriyan, J. (1999). Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3:639–648.
Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942.
Sedlacek, H.H. (2000). Kinase inhibitors in cancer therapy. Drugs 59:435–476.
Shakespeare, W.C. (2001). SH2 domain inhibition: a problem solved? Curr. Opin. Chem. Biol. 5:409–415.
Shakespeare, W.C., Bohacek, R.S., Azimioara, M.D., Macek, K.J., Luke, G.P., Dalgarno, D.C., Hatada, M.H., Lu, X., Violette, S.M., Bartlett, C., and Sawyer, T.K. (2000a). Structure-based design of novel bicyclic inhibitors for the Src SH2 domain. J. Med. Chem. 43:3815–3819.
Shakespeare, W., Yang, M., Bohacek, R., Cerasoli, F., Stebbins, K., Sundaramoorthi, R., Azimioara, M., Vu, C., Pradeepan, S., Metcalf, C. III, Haraldson, C., Merry, T., Dalgarno, D., Narula, S., Hatada, M., Lu, X., van Schravendijk, M.R., Adams, S., Violette, S., Smith, J., Guan, W., Bartlett, C., Herson, J., Iuliucci, J., Weigele, M., and Sawyer, T. (2000b). Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 97:9373–9378.
Shakespeare, W.C., Metcalf, C.A. III, Wang, Y., Sundaramoorthi, R., Keenan, T., Weigele, M., Bohacek, R.S., Dalgarno, D.C. and Sawyer, T.K. (2003a). Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr. Opin. Drug Disc. Devel. 6:729–741.
Shakespeare, W., Wang, Y., Metcalf, C., Sundaramoorthi, R., Keenan, T., Bohacek, R., vanSchravendijk, M.R., Snodgrass, J., Dilauro, A., Roeloffzen, S., Liu, S., Saltmarsh, J., Paramanathan, G., Pradeepan, S., Naugle, J., Wardwell, S., Bogus, J., Keats, J., Ram, M., Andrade, L., Liou, S., Narula, S., Adams, S., Boyce, B., Xing, L., Weigele, M., Dalgarno, D., Iuliucci, J., and Sawyer, T. (2003b). Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent activity in an animal model of osteolytic bone metastasis. Proc. AACR 44:A3871.
Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature 385:602–609.
Slate, D.L, Lee, R.H., Rodriguez, J., and Crews, P. (1994). The marine nature product, halistanol trisulfate, inhibits pp60v-src protein tyrosine kinase activity. Biochem. Biophys. Res. Commun. 203:260–264.
Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R.J., Neel, B.G., Rirge, R.B., Fajardo, J.E., Chou, M.M., Hanafusa, H., Schaffhausen, B., and Cantley, C.L. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell 72:767–778.
Soriano, P., Montgomery, C., Geske, R., and Bradley, A. (1991). Targeted disruption of the c-src protooncogene leads to osteoporosis in mice. Cell 64:693–702.
Sotriffer, C., and Klebe, G. (2002). Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. Farmaco 57:243–251.
Staley, C.A., Parikh, N.U., and Gallick, G.E. (1997). Decreased tumorigenicity of a human colon carcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ. 8:269–274.
Stankovic, C.J., Plummer, M.S., and Sawyer, T.K. (1997a). Peptidomimetic ligands for Src homology-2 domains. Adv. Amino Acid Mimet. Peptidomimet. 1:127–163.
Stankovic, C.J., Surendran, N., Lunney, E., Plummer, M.S., Para, K., Shahipour, A., Fergus, J.H., Marks, J.S., Herrera, R., Hubbell, S.E., Humblet, C., Saltiel, A.R., Stewart, B.H., and Sawyer, T.K. (1997b). The role of 4-phosphonodifluoromethyl-and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg. Med. Chem. Lett. 7:1909–1914.
Stover, D.R., Lydon, N.B., and Nunes, J.J. (1999). Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis. Curr. Opin. Drug Discov. Dev. 2:274–285.
Strawn, L.M., and Shawver, L.K. (1998). Tyrosine kinases in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opin. Invest. Drugs 7:533–573.
Summy, J.M., and Gallick, G.E. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastas. Rev. 22:337–358.
Sundaramoorthi, R., Kawahata, N., Yang, M.G., Shakespeare, W.C., Metcalf, C.A. III, Wang, Y., Merry, T., Eyermann, C.J., Bohacek, R.S., Narula S., Dalgarno, D.C., Sawyer, T.K. (2003). Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Biopolymers (Pept. Sci.) 71:717–729.
Susa, M., and Teti, A. (2000). Tyrosine kinase Src inhibitors: potential therapeutic applications. Drug News Perspect. 13:169–175.
Susa, M., Missbach, M., and Green J. (2000). Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol. Sci. 21:489–495.
Talamonti, M.S., Roh, M.S., Curley, S.A., and Gallick, G.E. (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 91:3–60.
Tanaka, S., Amling, M., Neff, L., Peyman, A., Uhlmann, E., Levy, J.B., and Baron, R. (1996). c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528–531.
Tatton, L., Morley, G.M., Chopras, R. and Khwaja, A. (2003). The Src-selective kinase inhibitor PP1 also inhibits Kit and BcrAbl tyrosine kinases. J. Biol. Chem. 278:4847–4853.
Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. Science 289:1504–1508.
Thomas, J.W., Ellis, B., Boerner, R.J., Knight, W.B., White, G.C., II, and Schaller, M.D. (1998). SH2-and SH3-mediated interactions between focal adhesion kinase and Src. J. Biol. Chem. 273:577–583.
Thomas, S.M., and Brugge, J.S. (1997) Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:513–609.
Toledo, L.M., Lydon, N.B., and Elbaum, D. (1999). The structure-based design of ATP-site directed protein kinases. Curr. Med. Chem. 6:775–805.
Traxler, P. (1997). Protein tyrosine kinase inhibitors in cancer treatment. Expert Opin. Ther. Patents 7:571–587.
Traxler, P. (1998). Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin. Ther. Patents 8:1599–1628.
Tsai, Y.T., Su, Y.H., Fang, S.S., Huang, T.N., Qiu, Y., Jou, Y.S., Shih, H.M., Kung, H.J., and Chen, R.H. (2000). Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol. Cell. Biol. 20:2043–2054.
Tsatsanis, C., and Spandidos, D.A. (2000). The role of oncogenic kinases in human cancer. Int. J. Mol. Med. 5:583–590.
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R.P., and Jove, R. (1998). STAT3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18:2545–2552.
Uehara, Y., and Fukuzawa, H. (1991). Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol. 201:370–379.
Uludag, H. (2002). Bisphosphonates as a foundation of drug delivery to bone. Curr. Pharm. Des. 8:929–1944.
Van Oijen, M.G., Rijkseng, G., Ten Broek, F.W., and Slootweg, P.J. (1998). Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J. Oral Pathol. Med. 27:147–152.
Verbeek, B.S., Vroom, T.M., Adriaansen-Slot, S.S., Ottenhoff-Kalff, A.E., Geertzema, J.G., Hennipman, A., and Rijksen, G. (1996). c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 180:383–388.
Vetter, S.W., and Zhang, Z.Y. (2002). Probing the phosphopeptide specificities of protein tyrosine phosphatases, SH2 and PTB domains with combinatorial library methods. Curr. Protein Pept. Sci. 3:265–397.
Vidal, M., Gigoux, V., and Garbay, C. (2001). SH2 and SH3 domains as targets for antiproliferative agents. Crit. Rev. Oncol. Hematol. 40:175–186.
Violette, S.M., Shakespeare, W.C., Bartlett, C., Guan, W., Smith, J.A., Rickles, R.J.; Bohacek, R.S., Holt, D.A., Baron, R., and Sawyer, T.K. (2000). A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chem. Biol. 7:225–235.
Violette, S.M., Guan, W., Bartlett, C., Smith, J.A., Bardelay, C., Antoine, E., Rickles, R.J., Mandine, E., van Schravendijk, M.R., Adams, S. E., Lynch, B.A., Shakespeare, W.C., Yang, M., Jacobsen, V.A., Takeuchi, C.S., Macek, K.J., Bohacek, R.S., Dalgarno, D.C., Weigele, M., Lesuisse, D., Sawyer, T.K., and Baron, R. (2001). Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 28:54–64.
von Bubnoff, N., Veach, D.R., Miller, T., Li, W., Sanger, J., Peschel, C., Bornmann, W.G., Clarkson, B., and Duyster, J. (2003). Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res. 63:6395–6404
von Stechow, D., Alexander, J., Chorev, M., Fish, S., Iuliucci, J., Wang, Y., Metcalf, C., Keenan, T., Sundaramoorthi, R., Shakespeare, W., van Schravendijk, M.R., Dalgarno, D., and Sawyer, T. (2001). Novel Src tyrosine kinase inhibitors prevent ovariectomy-induced bone loss in a Swiss-Webster mouse model of post-menopausal osteoporosis. J. Bone Miner. Res. 16(Suppl. 1), Abstract F425.
Vu, C.B. (2000). Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2, and ZAP-70. Curr. Med. Chem. 7:1081–1100.
Waksman, G. Kominos, D., Robertson, S.C., Pant, N., Baltimore, D., Birge, R.B., Cowburn, D., Hanafusa, H., Mayer, B.J., Overduin, M., Resh, M.D., Rios, C.B., Silverman, L., and Kuriyan, J. (1992). Crystal structure of the phosphotyrosine recognition domain SH2 of v-Src complexed with tyrosinephosphorylated peptides. Nature 358:646–653.
Waksman, G., Shoelson, S.E., Pant, N., Cowburn, D., and Kuriyan, J. (1993). Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72:779–790.
Waksman, G., Kumaran, S., and Lubman, O. (2004). SH2 domains: role, strucure and implications for molecular medicine. Exp. Rev. Molec. Med. 6:1–21.
Wang, Y.D., Miller, K., Boschelli, D.H., Ye, F., Wu, B., Floyd, M.B., Powell, D.W., Wissner, A., Weber, J.M., Boschelli, F. (2000). Inhibitors of Src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. 10:2477–2480.
Wang, Y., Metcalf, C.A., III, Shakespeare, W.C., Sundaramoorthi, R., Keenan, T.P., Bohacek, R.S., van Schravendijk, M.R., Violette, S.M., Narula, S.S., Dalgarno, D.C., Haraldson, C., Keats, J., Liou, S., Mani, U., Pradeepan, S., Ram, M., Adams, S., Weigele, M., and Sawyer TK. (2003). Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. 13:3067–3070.
Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., and Gray, N. (2003a). Src family kinases: potential targets for the treatment of human cancer and leukemia. Curr. Pharm. Design 9:2043–2059.
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., and Hallek, M. (2003b). Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101:664–672.
Waszkowycz, B. (2002). Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discov. Devel. 5:407–413.
Wisniewski, D., Lambek, C.I., Liu, C., Strife, A., Veach, D.R., Nagar, B., Young, M.A., Schindler, T., Bornmann, W.G., Bertino, J.R., Kuriyan, J., and Clarkson, B. (2002). Characterization of potent inhibitors of the Bcr-Abl and the c-Kit receptor tyrosine kinases. Cancer Res. 62:4244–4255.
Woolfrey, J.R., and Weston, G.S. (2002). The use of computational methods in the discovery and design of kinase inhibitors. Curr. Pharm. Des. 8:1527–1545.
Wong, B.R., Besser, D., Kim, N., Arron, J.R., Vologodskaia, M., Hanafusa, H., and Choi, Y. (1999). TRANCE, a TNF family member, activates Atk/PKB through a signalling complex involving TRAF6 and c-Src. Mol. Cell 4:1041–1049.
Xu, W., Doshi, A., Lei, M., Eck, M.J., and Harrison S.C. (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3:629–638.
Xu, W., Harrison, S.C., and Eck, M.J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385:595–602.
Yamaguchi, H., and Hendrickson, W.A. (1996). Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384:484–489.
Yoneda, T., Lowe, C., Lee, C.-H., Gutierrez, G. Niewolna, M., Williams, P.J., Izbicka, E., Uehara, Y., Mundy, G. R. (1993). Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J. Clin. Invest. 91:2791–2795.
Zhu, X., Kim, J.L., Newcomb, J.R., Rose, P.E., Stover, D.R., Toledo, L.M., Zhao, H., Morgenstern, K.A. (1999). Structural analysis of the lymphocyte-specific Lck in complex with non-selective and Src family-selective kinase inhibitors. Struct. Fold. Des. 7:651–661.
Zimmerman, J., Buchdunger, E., Mett, H., Meyer, T., and Lydon, N.B. (1997). Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7:187–192.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Sawyer, T.K. et al. (2005). SMART Drug Design: Novel Phosphopeptide and ATP Mimetic-Based Small Molecule Inhibitors of the Oncogenic Protein Kinase pp60src (Src). In: Waksman, G. (eds) Proteomics and Protein-Protein Interactions. Protein Reviews, vol 3. Springer, Boston, MA. https://doi.org/10.1007/0-387-24532-4_11
Download citation
DOI: https://doi.org/10.1007/0-387-24532-4_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24531-7
Online ISBN: 978-0-387-24532-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)